Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Dysregulation of the ASPP Protein Family (Apoptosis Stimulating Proteins of TP53) Is a Common Feature in High-Risk Acute Myeloid Leukemia (AML)

Kerstin Maria Kampa-Schittenhelm, MD, Max Kaiser, Mihada Bajrami Saipi, Bianca Walter, Gunnar Blumenstock, Lothar Kanz, Marcus M Schittenhelm, MD

Blood (2017) 130 (Supplement 1): 1231.

https://doi.org/10.1182/blood.V130.Suppl_1.1231.1231

Published: 2017

Journal Articles

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Kerstin Maria Kampa-Schittenhelm, MD, Hans-Joerg Buehring, Michael Bonin, Wichard Vogel, MD, Lothar Kanz, Prof. Dr. MD, Thomas Haverkamp, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2437.

https://doi.org/10.1182/blood.V126.23.2437.2437

Published: 2015

Journal Articles

Attenuation of Apoptosis-Stimulating Protein of p53-2 (ASPP2) Promotes IL-3-Independent Growth and Enhances Cytogenetic Abnormalities after Gamma-Irradiation in Mouse Hematopoietic Cells - Mimicking Early Leukemogenesis of Therapy-Associated Human AML

Kerstin Maria Kampa-Schittenhelm, MD, Ulrike Mau-Holzmann, Lothar Kanz, Prof. Dr. MD, Charles Lopez, MD PhD, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2460.

https://doi.org/10.1182/blood.V126.23.2460.2460

Published: 2015

Journal Articles

FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.

Kerstin M Kampa, MD, Sandra Mueller, PhD, Katharina-Henriette Rasp, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 1740.

https://doi.org/10.1182/blood.V114.22.1740.1740

Published: 2009

Journal Articles

Insights Into the Role of ASPP2 (Apoptosis Stimulating Protein of p53-2) in Lymphomagenesis.

Kerstin M Kampa, MD, Sandra Mueller, PhD, Michael Bonin, PhD, Marcus M Schittenhelm, MD, Charles D Lopez, MD, PhD

Blood (2009) 114 (22): 1967.

https://doi.org/10.1182/blood.V114.22.1967.1967

Published: 2009

Journal Articles

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Kerstin M Kampa, MD, Tanja Grandl, Sandra Mueller, Emmanuel Normant, PhD, Michael Walter, PhD, Wolfgang Schuetz, PhD, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 2753.

https://doi.org/10.1182/blood.V114.22.2753.2753

Published: 2009

Journal Articles

Apoptosis Stimulating Protein of p53 (ASPP2) Heterozygous Mice Are Lymphoma-Prone and Display Attenuated Apoptosis and Cell Cycle Checkpoints

Kerstin Maria Kampa, MD, Jared Acoba, MD, Dexi Chen, MD, PhD, Hun-Joo Lee, Kelly Beemer, Joel Gay, Zhyi Zhu, Emerson Padiernos, Marcus M Schittenhelm, MD, Lothar Kanz, MD, Christopher Corless, MD, PhD, Charles Lopez, MD, PhD

Blood (2008) 112 (11): 2844.

https://doi.org/10.1182/blood.V112.11.2844.2844

Published: 2008

Journal Articles

Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML.

Marcus M. Schittenhelm, MD, Kerstin M. Kampa, MD, Kevin W.H. Yee, MD, Lothar Kanz, MD,PhD, Michael C. Heinrich, MD,PhD

Blood (2007) 110 (11): 4213.

https://doi.org/10.1182/blood.V110.11.4213.4213

Published: 2007

Journal Articles

Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs.

Marcus M. Schittenhelm, MD, Kerstin M. Kampa, MD, Sharon Shiraga, Lothar Kanz, MD, PhD, Michael C. Heinrich, MD, PhD

Blood (2007) 110 (11): 2370.

https://doi.org/10.1182/blood.V110.11.2370.2370

Published: 2007

Journal Articles

Tandutinib (MLN518), a Potent FLT3 Inhibitor, Synergizes with Cytarabine and/or Daunorubicin in a Sequence-Independent Manner.

Marcus M. Schittenhelm, MD, Kevin W. Yee, M.D., Kerstin M. Kampa, M.D., Michael C. Heinrich, M.D.

Blood (2006) 108 (11): 1374.

https://doi.org/10.1182/blood.V108.11.1374.1374

Published: 2006

Journal Articles

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Marcus M. Schittenhelm, MD, Sharon Shiraga, Arin Schroeder, Amie S. Corbin, Diana Griffith, Francis Y. Lee, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD, Michael C. Heinrich, MD

Blood (2005) 106 (11): 3358.

https://doi.org/10.1182/blood.V106.11.3358.3358

Published: 2005

NARROW

Dysregulation of the ASPP Protein Family (Apoptosis Stimulating Proteins of TP53) Is a Common Feature in High-Risk Acute Myeloid Leukemia (AML)

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Attenuation of Apoptosis-Stimulating Protein of p53-2 (ASPP2) Promotes IL-3-Independent Growth and Enhances Cytogenetic Abnormalities after Gamma-Irradiation in Mouse Hematopoietic Cells - Mimicking Early Leukemogenesis of Therapy-Associated Human AML

FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.

Insights Into the Role of ASPP2 (Apoptosis Stimulating Protein of p53-2) in Lymphomagenesis.

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Apoptosis Stimulating Protein of p53 (ASPP2) Heterozygous Mice Are Lymphoma-Prone and Display Attenuated Apoptosis and Cell Cycle Checkpoints

Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML.

Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs.

Tandutinib (MLN518), a Potent FLT3 Inhibitor, Synergizes with Cytarabine and/or Daunorubicin in a Sequence-Independent Manner.

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only